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A B S T R A C T
This year the medical community was pleasantly surprised
by the results of the first large outcome trial that primarily ex-
amined the renal effects of the sodium-glucose cotransporter 2
(SGLT2) inhibitor canagliflozin (CANA) in subjects with
diabetes and impaired kidney function. The Evaluation of the
Effects of Canagliflozin on Renal and Cardiovascular Outcomes
in Participants With Diabetic Nephropathy (CREDENCE) trial
showed that CANA, relative to placebo, reduces the risk for
end-stage renal disease, doubling of creatinine or renal death by
34% [hazard ratio 0.66 (95% confidence interval 0.53–0.81].
These effects were consistent across baseline estimated glomer-
ular filtration rate (eGFR) and haemoglobin A1c subgroups. In
this review we combine the results of the CREDENCE trial with
those of several cardiovascular outcome trials with SGLT2
inhibitors and show that, unexpectedly, patients with lower
eGFR levels may have greater benefit with respect to cardiovas-
cular outcome than patients with normal kidney function. The
cardio- and renoprotective effects of SGLT2 inhibitors seem to
be independent of their glucose-lowering effects, as shown in
several post hoc analyses. In this review we discuss the alleged
mechanisms of action that explain the beneficial effects of this
novel class of drugs. Moreover, we discuss whether these find-
ings indicate that this class of drugs may also be beneficial in
non-diabetic chronic kidney diseases.
Keywords: cardiovascular, CKD, clinical trial, diabetes melli-
tus, GFR
I N T R O D U C T I O N
The proximal tubule in the kidney plays an important role in
glucose homoeostasis by reabsorbing glucose from pre-urine
back into the blood. Glucose is cotransported together with
sodium by sodium-glucose cotransporter 1 (SGLT1), located in
the S3 segment of the proximal tubule, and by SGLT2 located in
the S1 segment of the renal proximal tubule. The vast majority
of filtered glucose is reabsorbed by SGLT2. These SGLTs were
discovered in the late 1970s/early 1980s [1]. By blocking SGLT1
and SGLT2 competitively with phlorizin, an old natural drug
obtained from the bark of apple trees, urinary glucose excretion
increased and plasma glucose normalized in diabetic rats [2, 3].
Yet, phlorizin was not an ideal candidate glucose-lowering drug
because of its low oral bioavailability and unselective SGLT1
and SGLT2 inhibition, with intestinal side effects as a result of
SGLT1 inhibition, such as diarrhoea and malabsorption [3, 4].
Later on, specific SGLT2 inhibitors were developed as glucose-
lowering drugs with fewer intestinal side effects. These drugs
had an adequate half-life (T1/2)to allow oral once-daily adminis-
tration [dapagliflozin (DAPA) T1/2 12.2 h, canagliflozin
(CANA) T1/2 11–13 h and empagliflozin (EMPA) T1/2 12.4 h]
[5]. In 2012, the first SGLT2 inhibitor, DAPA, was given mar-
keting authorization by the European Medicines Agency as a
glucose-lowering drug in patients with type 2 diabetes mellitus,
followed by approval from the US Food and Drug
Administration in 2014 [3]. These regulatory agencies required
the industry to conduct large cardiovascular outcome trials to
investigate potential harmful cardiovascular side effects. In
2015, the first outcome trial was published with the SGLT2 in-
hibitor EMPA [6]. This trial, together with the two cardiovascu-
lar outcome trials with CANA and DAPA that were published
in the years thereafter, showed unexpected cardiovascular and
renal beneficial effects of these drugs in patients with type 2 dia-
betes [6–10]. These patients often received lipid-lowering, anti-
hypertensive and antiproteinuric treatment with renin–
angiotensin–aldosterone system (RAAS) blockade, but despite
these interventions, the residual risk for progression of diabetic
kidney disease remains high [11]. The development of SGLT2
inhibitors provides new perspectives for these patients.
Six to 10 years ago, Phase 2 and 3 studies already showed
that SGLT2 inhibitors not only lowered plasma glucose, but
also decreased blood pressure, body weight (BW) and proteinuria
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[12–14]. The recent large cardiovascular outcome trials
Empagliflozin Cardiovascular Outcome Event Trial in Type 2
Diabetes Mellitus Patients (EMPA-REG OUTCOME) with
EMPA, CANagliflozin cardioVascular Assessment Study
(CANVAS) with CANA and Multicenter Trial to Evaluate the
Effect of Dapagliflozin on the Incidence of Cardiovascular Events
(DECLARE-TIMI58 with DAPA reproduced these beneficial
effects and also showed that SGLT2 inhibitors lowered the risk for
renal events by 34–47%, the risk for cardiovascular events by 7–
14% and the risk for hospitalization for heart failure by 30%
(Table 1). Renal events were defined differently in these three trials
as a composite of incidence of kidney replacement therapy/end-
stage kidney disease or renal- or cardiovascular death, combined in
the EMPA-REG OUTCOME and CANVAS trials with progres-
sion to macroalbuminuria and/or doubling of serum creatinine
and in the DECLARE-TIMI58 trial with a 40% reduction in esti-
mated glomerular filtration rate (eGFR) (Table 1). The results
obtained in these trials were very promising. However, they were
not designed to examine changes in renal outcomes, but to test car-
diovascular safety in a non-inferiority design compared with pla-
cebo. Therefore specific, well-powered renal outcomes trials were
launched and small-scale mechanistic studies were initiated to ob-
tain more insight into the underlying renoprotective mechanisms.
This review will focus on the effects and the use of SGLT2
inhibitors in patients with chronic kidney disease (CKD). We
will elaborate on the mechanisms underlying the renoprotective
effects and question whether, based on these mechanisms,
SGLT2 inhibitors might also be indicated for non-diabetic
patients with a CKD.
Could SGLT2 inhibitors also be beneficial in patients
with reduced kidney function?
SGLT2 inhibitors were officially indicated as an adjunct to
diet and exercise to lower blood glucose levels in adults with
type 2 diabetes mellitus. The labels do not allow the use of these
drugs in subjects with impaired kidney function. Likewise, until
recently, regulatory agencies and guidelines advised against pre-
scribing SGLT2 inhibitors to patients with an eGFR <60 mL/
min/1.73 m2 [15–18]. This recommendation was based on stud-
ies illustrating that the glucose-lowering effect of SGLT2 inhibi-
tors is less in people with lower kidney functions [6, 9, 12]. A
smaller mean haemoglobin A1c (HbA1c) difference was also
found in the Evaluation of the Effects of Canagliflozin on Renal
and Cardiovascular Outcomes in Participants With Diabetic
Nephropathy (CREDENCE) trial, a large outcome trial with
CANA that specifically included subjects with lower kidney
functions when compared with the CANVAS trial (mean base-
line eGFR 56 versus 77 mL/min/1.73 m2, respectively). The
effects on HbA1c throughout the trial were0.25% [95% confi-
dence interval (CI) 0.20% to 0.31%] and 0.58% (95% CI
0.61% to0.56%), respectively [10, 19]. This is not surprising
since the blood glucose–lowering effect of this class of drugs is
dependent on the number of intact nephrons [20]. However,
multiple studies have suggested that reductions in blood pres-
sure, BW and proteinuria are independent of glucose control
and may persist in people with lower kidney functions [21–24].
For instance, Heerspink et al. [24] showed that 2 years of treat-
ment with CANA compared with glimepiride resulted in a
smaller annual eGFR decline and a relatively larger urinary
Table 1. Summary of outcome trials with SGLT2 inhibitors
Trial and design Main inclusion criteria Main cardiovascular outcomes Main renal outcomes
DECLARE-TIMI 58
DAPA 10 mg or placebo once daily
N¼ 17 160
eGFR¼ 85.2 mL/min/1.73 m2
Median follow-up: 4.2 years
Type 2 diabetes
HbA1c 6.5–12.0%
Established atherosclerotic CVD or mul-
tiple risk factors for atherosclerotic
CVD
Creatinine clearance 60 mL/min
17% reduction [HR 0.83 (95% CI
0.73–0.95), P¼ 0.005] of the com-
posite of cardiovascular death or
hospitalization for heart failure.
No effect [HR 0.93 (95% CI 0.84–
1.03), P¼ 0.17] on MACEs
47% reduction [HR 0.53
(95% CI 0.43–0.66),
P< 0.0001] of renal-specific
composite outcome
EMPA-REG OUTCOME
EMPA 10 mg, EMPA 25 mg,
or placebo once daily
N¼ 7020
eGFR¼ 74.1 mL/min/1.73 m2
Median follow-up: 3.1 years
Type 2 diabetes
HbA1c 7.0–9.0% without glucose-lower-
ing therapy or HbA1c 7.0–10.0% with
stable glucose-lowering therapy
BMI45 kg/m2
Established CVD
eGFR30 mL/min/1.73 m2
14% reduction [HR 0.86 (95% CI
0.74–0.99), P¼ 0.04] of composite
of death from cardiovascular
causes, non-fatal myocardial
infarction or non-fatal stroke
39% reduction [HR 0.61
(95% CI 0.53–0.70),
P< 0.001] of renal-specific
composite outcome
CANVAS
CANA 300 mg, CANA 100 mg
or placebo once daily
N¼ 10 142
eGFR¼ 76.5 mL/min/1.73 m2
Median follow-up: 2.4 years
Type 2 diabetes
HbA1c 7.0–10.5%
Established CVD or two or more risk
factors for CVD
eGFR30 mL/min/1.73 m2
14% reduction [HR 0.86 (95% CI
0.75–0.97), P¼ 0.02] of composite
of death from cardiovascular
causes, non-fatal myocardial
infarction or non-fatal stroke
40% reduction [HR 0.60
(95% CI 0.47–0.77)] of re-
nal-specific composite
outcome
CREDENCE
CANA 100 mg or placebo once daily
N¼ 4401
eGFR¼ 85.2 mL/min/1.73 m2
Median follow-up: 2.6 years
Type 2 diabetes
30 years of age
HbA1c 6.5–12.0%
Established CKD: eGFR 30–90 mL/min/
1.73 m2 and UACR 300–5000 mg/g
31% reduction [HR 0.69 (95% CI
0.57–0.83), P< 0.001] of compos-
ite of cardiovascular death or hos-
pitalization for heart failure
34% reduction [HR 0.66
(95% CI 0.53–0.81),
P< 0.001] of renal-specific
composite outcome
BMI, body mass index; MACEs, major adverse cardiovascular events.
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albumin:creatinine ratio (UACR) reduction in subjects with a
higher baseline UACR, while the differences in HbA1c between
the groups were modest. Adjusting the analysis for these mod-
est differences in HbA1c did not alter the results [24]. Three
other groups examined the use of SGLT2 inhibitors in subjects
with lower kidney functions and also found attenuated effects
on HbA1c but persistent beneficial effects on blood pressure,
BW and proteinuria [21–23]. The effects on cardiovascular and
renal endpoints might therefore be different from the effects on
HbA1c in patients with a reduced kidney function. These find-
ings also suggest that SGLT2 inhibitors may have potential ben-
efits in subjects with CKD, perhaps even in non-diabetic
subjects.
Post hoc analyses of the cardiovascular safety trials evaluated
whether these short-term beneficial effects can be translated
into risk reductions for cardiovascular and renal events in
patients with type 2 diabetes mellitus and established CKD
[8, 25–27]. The number of subjects with a baseline
eGFR<60 mL/min/1.73 m2 was 1819 (25.9%), 1265 (7.4%) and
2039 (20.1%), in the EMPA-REG OUTCOME, DECLARE-
TIMI58 and CANVAS trials, respectively. When looking at the
EMPA-REG OUTCOME trial, it was concluded that with
EMPA in the subjects with a baseline eGFR<60 mL/min/
1.73 m2, a similar risk reduction for the primary cardiovascular
outcome was obtained as in subjects with an eGFR60 mL/
min/1.73 m2 [26]. The relative risk reductions for the primary
cardiovascular outcome [3-point major adverse cardiovascular
events (MACEs)], cardiovascular death and hospitalization
for heart failure were also consistent across baseline eGFR
subgroups in the CANVAS programme [25].
In contrast with the cardiovascular outcome trials, the
CREDENCE trial was specifically powered to assess cardio-
renal outcomes in people with type 2 diabetes and CKD. People
with an eGFR between 30 and 90 mL/min/1.73 m2 and an
UACR between 300 and 5000 mg/g were included and random-
ized to receive treatment with CANA 100 mg/day or placebo.
The baseline mean eGFR level was 56 mL/min/1.73 m2 and the
median UACR was 927 mg/g. The trial was stopped early be-
cause of overwhelming efficacy. The pre-specified efficacy crite-
ria for early cessation of the trial were achieved at the interim
analysis that was conducted after the occurrence of the primary
composite renal outcome in 405 patients. Relative to placebo,
CANA reduced the risk for end-stage renal disease, doubling of
creatinine or renal death by 34% [hazard ratio (HR) 0.66, 95%
CI 0.53–0.81]. Also in this trial, the effects were reported to be
consistent across baseline eGFR categories [19]. Nearly all
patients included in the CREDENCE trial were on a stable dose
of RAAS blockade. Adding CANA slowed the progression of
eGFR decline by 1.52 mL/min/1.73 m2/year compared with pla-
cebo and did not result in an increase in the risk for acute kid-
ney failure [19]. Other renal outcome trials with EMPA
(EMPA-KIDNEY) and DAPA (DAPA-CKD) are ongoing.
Taken together, the data of the outcome trials in patients
with type 2 diabetes suggest that SGLT2 inhibitors reduced car-
diovascular and renal endpoints regardless of baseline renal
function [8, 19, 25, 26]. Surprisingly, a different picture is
obtained when data of these trials are combined as shown in
Figure 1. This figure shows the primary cardiovascular and re-
nal outcomes of the trials with DAPA, EMPA and CANA per
baseline eGFR subgroup (<45, 45–60, 60–90 and90 mL/min/
1.73 m2). Subjects with lower kidney function seem to have
greater beneficial effects on cardiovascular outcomes than sub-
jects with better kidney function with respect to relative as well
as absolute risk reduction. In line with this, a recent meta-
analysis also showed that patients with a lower baseline eGFR
have greater reductions of the risk for hospitalization for heart
failure than patients with a higher baseline eGFR (P for inter-
action¼ 0.007) [28]. These results suggest that from a cardio-
vascular perspective, especially patients with impaired kidney
function benefit from SGLT2 inhibition. Looking at the renal
outcomes in Figure 1, one can observe a beneficial effect of
SGLT2 inhibitors in all eGFR subgroups. However, the trend
seems opposite to the trend for cardiovascular outcomes. The
magnitude of the benefit of SGLT2 inhibition appears to be
smaller in people with lower eGFR levels. A similar pattern was
observed in the meta-analysis of Neuen et al. (Ptrend for eGFR
subgroup 0.073) [27]. Yet, when looking at absolute benefit in
Figure 1, expressed as the estimated number needed to treat
during 5 years to prevent one event, it shows that a still better
treatment efficacy is found in the lower eGFR subgroups. For
example, the average number needed to treat to prevent a renal
event is 21 in the subgroup with eGFR<45 mL/min/1.73 m2,
while it is 30, 62 and 79 in the subgroups of patients with an
eGFR 45–60, 60–90 and 90 mL/min/1.73 m2, respectively
(Figure 1). These data in Figure 1 suggest that, despite the fact
that SGLT2 inhibitors were originally thought to have less effi-
cacy in subjects with lower kidney function, this class of drugs
actually has better treatment efficacy in subjects with lower kid-
ney function, especially when looking at cardiovascular events,
but possibly also with respect to the absolute number of renal
events to be prevented.
Regarding safety, it can be stated that in the cardiovascular
outcome trials in patients with type 2 diabetes, the SGLT2
inhibitors were generally well tolerated. Overall, there was no
increased risk for hyperkalaemia or acute kidney injury [28].
Only the risk for mycotic genital infections appeared to be in-
creased, which is related to the urinary excretion of glucose
[29, 30]. In the CREDENCE trial, no surprising or unknown ad-
verse events were detected. Only the rates of ketoacidosis were
higher in the CANA group than the placebo group (2.2 versus
0.2/1000 patients), but the total event rate was low [19].
Subgroup analyses according to baseline kidney function are
yet not available.
Based on the new outcome and safety trials, both the
American Diabetes Association (ADA) and the European
Association for the Study of Diabetes published in 2018 a con-
sensus statement on the management of hyperglycaemia in
patients with type 2 diabetes. They now advise considering the
use of SGLT2 inhibitors in patients with type 2 diabetes and
CKD with or without cardiovascular disease (CVD) (if eGFR is
adequate) [17, 31]. The revised ADA guideline also included
that DAPA is approved for use in patients with type 2 diabetes
and an eGFR45 mL/min/1.73 m2, instead of 60 mL/min/
1.73 m2 [17]. Given the data that are presented in this review,
SGLT2 inhibitors in non-diabetic kidney disease i35
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we propose that SGLT2 inhibitors can also be used in subjects
with CKD and even lower kidney function.
Mechanisms underlying the renoprotective effects of
SGLT2 inhibitors
After it became clear that the beneficial renal effects of
SGLT2 inhibitors were largely independent of the blood glu-
cose–lowering effect of these drugs, intensive research focused
on disclosing what mechanism may underlie their renoprotec-
tive effect. Multiple mechanisms have been hypothesized to be
responsible [32]. Several recent reviews have addressed the vari-
ous alleged mechanisms leading to renal protection in detail
[33]. Therefore this issue will be only briefly discussed here.
Systemic mechanisms involve a decrease in HbA1c, BW, in-
flammation and blood pressure that are caused by SGLT2 inhi-
bition, which are known risk factors for the development and
progression of CKD [32]. SGLT2 inhibition might also contrib-
ute to reverse systemic inflammatory and fibrotic processes, as
indicated by the decreases in plasma tumor necrosis factor re-
ceptor 1, inerleukin-6 (IL-6), matrix metallopeptidase 7 and fi-
bronectin 1 during CANA therapy [34]. The effects on blood
pressure are not restricted to daytime, as nocturnal blood pres-
sure is also decreased, which is a predictor for cardiovascular
and renal disease progression [35, 36]. A few articles have also
reported that SGLT2 inhibitors reduce aortic stiffness, but
others were not able to replicate this [37–39]. Decreases in
eGFR < 45
Empagliflozin (EMPA-REG)
Canagliflozin (CANVAS)
Canagliflozin (CREDENCE)
Subgroup mean (I-squared = 0.0%)
Trials Hazard ratio
(95% CI)
Estimated NNT
per 5 yr
0.79 (0.51, 1.21)
0.65 (0.41, 1.03)
0.70 (0.52, 0.93)
0.71 (0.57, 0.88)
SGLT2i
n/N
54/381
NA
79/678
Placebo
n/N
33/189
NA
111/687
20
11
11
13
eGFR 45 to 60
Dapagliflozin (DECLARE)
Empagliflozin (EMPA-REG)
Canagliflozin (CANVAS)
Canagliflozin (CREDENCE)
Subgroup mean (I-squared = 0.0%)
0.92 (0.69, 1.23)
0.93 (0.69, 1.26)
0.71 (0.53, 0.95)
0.83 (0.59, 1.17)
0.84 (0.72, 0.98)
85/606
122/831
NA
61/630
104/659
66/418
NA
75/636
28
52
18
24
31
eGFR 60 to 90
Dapagliflozin (DECLARE)
Empagliflozin (EMPA-REG)
Canagliflozin (CANVAS)
Canagliflozin (CREDENCE)
Subgroup mean (I-squared = 7.8%)
0.95 (0.82, 1.09)
0.76 (0.61, 0.94)
0.95 (0.80, 1.13)
0.90 (0.66, 1.23)
0.90 (0.82, 1.00)
367/3838
212/2423
NA
77/893
390/3894
139/1238
NA
83/876
141
23
91
77
104
eGFR > 90
Dapagliflozin (DECLARE)
Empagliflozin (EMPA-REG)
Canagliflozin (CANVAS)
Subgroup mean (I-squared = 0.0%)
0.94 (0.80, 1.10)
1.10 (0.77, 1.57)
0.84 (0.62, 1.13)
0.94 (0.82, 1.07)
304/4137
102/1050
NA
309/4025
44/488
NA
686
 
71
104
PRIMARY CARDIOVASCULAR OUTCOMES PER EGFR STRATUM (ML/MIN/1.73M2)
eGFR < 45
Empagliflozin (EMPA-REG)
Canagliflozin (CANVAS)
Canagliflozin (CREDENCE)
Subgroup mean (I-squared = 0.0%)
0.70 (0.36, 1.39)
0.65 (0.29, 1.48)
0.71 (0.56, 0.89)
0.70 (0.57, 0.88)
21/374
NA
122/678
14/189
NA
166/687
33
41
8
13
eGFR 45 to 60
Dapagliflozin (DECLARE)
Empagliflozin (EMPA-REG)
Canagliflozin (CANVAS)
Canagliflozin (CREDENCE)
Subgroup mean (I-squared = 0.0%)
0.60 (0.35, 1.02)
0.42 (0.24, 0.73)
0.78 (0.46, 1.13)
0.59 (0.43, 0.82)
0.60 (0.48, 0.74)
21/606
24/822
NA
58/630
38/659
26/416
NA
97/636
31
18
61
8
30
eGFR 60 to 90
Dapagliflozin (DECLARE)
Empagliflozin (EMPA-REG)
Canagliflozin (CANVAS)
Canagliflozin (CREDENCE)
Subgroup mean (I-squared = 11.7%)
0.54 (0.40, 0.73)
0.62 (0.38, 1.01)
0.58 (0.41, 0.84)
0.81 (0.58, 1.13)
0.63 (0.52, 0.76)
65/3838
37/2406
NA
65/893
121/3894
29/1232
NA
77/876
58
72
71
38
62
eGFR > 90
Dapagliflozin (DECLARE)
Empagliflozin (EMPA-REG)
Canagliflozin (CANVAS)
Subgroup mean (I-squared = 0.0%)
0.50 (0.34, 0.73)
0.49 (0.25, 0.95)
0.44 (0.25, 0.78)
0.48 (0.36, 0.64)
41/4137
18/1043
NA
79/4025
17/486
NA
90
39
47
79
RENAL OUTCOMES PER EGFR STRATUM (ML/MIN/1.73M2)
0.4 0.6 0.8 1.0 1.2 1.4 1.6
FIGURE 1: The primary cardiovascular and renal outcomes of the SGLT2 inhibitor outcome trials according to baseline eGFR subgroup.
Primary cardiovascular outcome was defined as 3-point MACEs. Renal outcomes were defined as sustained 40% decrease of eGFR, renal re-
placement therapy or end-stage kidney disease, or renal death. Only for the CREDENCE trial, the renal outcome was different, namely, dou-
bling of serum creatinine, end-stage kidney disease or death from renal or cardiovascular causes. The outcomes of subgroup ‘eGFR <60 mL/
min/1.73 m2’ of the DECLARE trial were used in our analysis and were depicted as subgroup ‘eGFR 45–60 mL/min/1.73 m2’ on the assumption
that there were no subjects with a baseline eGFR <45 mL/min/1.73 m2. A detailed description of the methods can be found in the
Supplementary data. NNT per 5yr, estimated number needed to treat during 5 years to prevent one event.
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blood pressure and arterial stiffness might decrease the cardiac
afterload. Furthermore, SGLT2 inhibitors might improve the
cardiac preload by lowering plasma volume as a result of os-
motic and natriuretic diuresis, secondary to urinary sodium
and glucose excretion [40, 41]. These systemic haemodynamic
mechanisms can beneficially influence the heart as well as the
kidneys.
SGLT2 inhibitors also promote specific intrarenal haemody-
namic changes that may protect glomeruli from high-pressure
damage. In 2014, Cherney et al. [42] showed that EMPA
attenuates glomerular hyperfiltration in subjects with type 1 di-
abetes. Subsequently he and others speculated about a causal
mechanism responsible for the attenuation of glomerular
hyperfiltration and for the typical ‘dip’ in GFR that is observed
directly after initiation of SGLT2 inhibitors [32]. It was
hypothesized that inhibition of SGLT2 decreased the SGLT2-
mediated reabsorption of sodium and glucose in the proximal
tubule, leading to increased delivery of glucose and sodium
chloride to the macula densa. The macula densa interprets this
as circulating volume expansion and via tubuloglomerular feed-
back either dilates the post-glomerular arteriole or constricts
the pre-glomerular arteriole. The latter was considered more
likely given the absence of changes in vasodilators in the urine.
Recently Kidokoro et al. [43] explored the glomerular haemo-
dynamic effects of EMPA in a type 1 diabetic mouse model by
visualizing the afferent and efferent arteriole with in vivo multi-
photon microscopy imaging techniques. They also measured
the single-nephron glomerular filtration. EMPA significantly
constricted the afferent arteriole within 30 min after adminis-
tration and consequently suppressed glomerular pressure and
single-nephron GFR. These effects were abolished by A1 adeno-
sine receptor blockade [43], suggesting that increased adenosine
generation following a restored tubuloglomerular feedback
mechanism is the key pathway for suppression of hyperfiltra-
tion during SGLT2 inhibition.
Inhibition of glucose and sodium reabsorption in the proxi-
mal tubule can also lead to other potential beneficial processes
in the kidney. For instance, it may improve mitochondrial
mechanisms, decrease hypoxic damage to proximal tubular
cells and reduce intrarenal inflammation. A recently published
post hoc analysis of a short-term clinical trial in subjects with
type 2 diabetes showed that DAPA, compared with placebo, in-
creased the excretion of urinary ketone bodies and urinary
metabolites that are linked to mitochondrial working mecha-
nisms, suggesting a beneficial effect on mitochondria [44].
Plasma metabolites were not changed and there was no correla-
tion with (change in) eGFR, suggesting that the effects were
kidney-specific [44]. The authors hypothesized that their results
could be explained by the increased availability of alternative
fuel sources and/or a reduced workload for proximal tubular
cells [44]. SGLT2 inhibition might increase the level of ketone
bodies as a result of enhanced lipolysis and reduced insulin lev-
els [45]. SGLT2 inhibition might also stimulate tubular ketone
body reabsorption by delivering sodium to the sodium mono-
carboxylate transporters (SMCT2 and SMCT1) that are depen-
dent on the sodium gradient to reabsorb ketones from the
lumen to the proximal tubular cells [45]. Ketone bodies are in-
volved in signalling functions and can act as an alternative
energy substrate for tubular cells along with glucose and free
fatty acids [45]. Furthermore, SGLT2 inhibition might re-
duce the workload for proximal tubular cells and decrease
hypoxia-induced proximal tubular damage, adenosine tri-
phosphate consumption and mitochondrial fragmentation
[44]. The decrease of hypoxic cell damage is illustrated by a
reduction in proximal tubular injury marker kidney injury
molecule-1 during SGLT2 inhibitor therapy [46]. Some
articles also reported reductions in other kidney injury
markers such as liver fatty acid–binding protein and N-acetyl
b-d-glucosaminidase and of inflammatory markers such as
IL-6 [34, 46, 47]. Inflammation is associated with the devel-
opment and decline of CKD, hence inhibition of inflamma-
tory pathways may also contribute to kidney protection [48].
It is not yet clear whether the above-described mechanisms
contribute equally to the favourable kidney outcomes or if cer-
tain mechanisms are more important than others. Future exper-
imental studies will have to provide more information and
clarification.
Extending to non-diabetic kidney disease
An important question is whether more people can benefit
from SGLT2 inhibitors in addition to subjects with diabetes.
At this moment it is unknown whether SGLT2 inhibitors af-
fect cardiovascular and renal outcome in non-diabetic subjects
since long-term clinical trials that investigate the effects of
SGLT2 inhibitors solely in the non-diabetic population are not
yet available. An indication may be obtained from studying
subgroups of the cardiovascular and renal outcome trials de-
fined by the level of glucose control. When meta-analysed, no
large differences are observed between subjects with baseline
HbA1c levels greater than or less than 8% (Figure 2) [8].
Recently the DAPA-HF trial was published that examined the
effects of DAPA in diabetic and non-diabetic subjects with
heart failure and reduced ejection fraction. Fifty-five percent
of the subjects in each treatment group were non-diabetic at
screening [49]. This trial also found a consistent beneficial ef-
fect on the primary composite endpoint, i.e. cardiovascular
death, hospitalization for heart failure or urgent heart failure
visit, between subjects with and without type 2 diabetes melli-
tus [HR 0.75 (95% CI 0.63–0.90) and HR 0.73 (95% CI 0.60–
0.88), respectively] [49]. There was no significant reduction of
the secondary composite renal endpoint, i.e. sustained reduc-
tion in eGFR of50%, end-stage kidney disease or death from
renal causes, but the total event numbers were very low (28
subjects in the DAPA group and 39 subjects in the placebo
group), and the number of serious renal events was signifi-
cantly lower in the DAPA group [49]. Hence it might be that
SGLT2 inhibitors also reduces eGFR decline in subjects with
well-regulated diabetes mellitus, pre-diabetes or even non-
diabetic CKD.
CKD can lead to nephron loss, resulting in an increased sin-
gle-nephron GFR in the remaining glomeruli. This causes
intraglomerular hypertension, which in turn can damage the
remaining glomeruli, resulting in proteinuria and glomerulo-
sclerosis. Looking at the renoprotective mechanisms of SGLT2
inhibitors, one can think of several kidney diseases that might
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benefit specifically from SGLT2 inhibitor therapy; for example,
obesity-induced CKD, hypertensive nephrosclerosis or focal
segmental glomerulosclerosis (FSGS). Obesity-induced CKD is
characterized by renal haemodynamic changes resulting in in-
creased renal plasma flow, GFR and filtration fraction, possibly
due to afferent arterial vasodilation [50]. SGLT2 inhibitors re-
duce glomerular hyperfiltration by afferent arterial vasocon-
striction and promote BW loss. Both are highly desirable effects
in patients with obesity-induced CKD. In patients with hyper-
tensive nephrosclerosis, increased renal plasma flow and glo-
merular hypertension are a result of arterial stiffening [51].
SGLT2 inhibition can potentially decrease intraglomerular
pressure and reduce arterial stiffness in these patients, which
could help to slow disease progression. Patients with FSGS or
with immunoglobulin A nephropathy might also benefit from
SGLT2 inhibition. These glomerular-based diseases often result
in proteinuria and hypertension [50]. Most patients respond to
RAAS blockade, but not all. Of note, RAAS inhibitors have dif-
ferent mechanisms of action than SGLT2 inhibitors. RAAS
inhibitors reduce the intraglomerular pressure by limiting an-
giotensin II–induced vasoconstriction of the efferent arteriole,
while SGLT2 inhibitors activate the tubuloglomerular feedback
mechanism, as explained in the previous section. SGLT2 inhibi-
tion can therefore be used as an alternative treatment or in addi-
tion to RAAS inhibition to further delay the decline of kidney
function. However, it is still unclear whether SGLT2 inhibitors
are truly effective in non-diabetic kidney diseases.
Currently several preclinical studies have been published
that examined the renal effects of SGLT2 inhibitors in non-
diabetic animals (Table 2). These studies show contradictory
results. Two studies did not find the renoprotective effects of
SGLT2 inhibitors. The other studies found a reduction of pro-
teinuria, kidney damage, inflammation and fibrosis after
SGLT2 inhibition (Table 2). The heterogeneity of the models
that were used makes it difficult to compare the results.
Summarizing, Zhang et al. [52] used a non-diabetic subtotally
nephrectomized rat model representing glomerular hyperfiltra-
tion and found no effects on proteinuria, GFR, glomeruloscle-
rosis or tubulointerstitial fibrosis. Ma et al. [53] used a mouse
model of CKD with tubulointerstitial injury and also did not
find beneficial effects on GFR, markers of fibrosis and tubular
injury and inflammation. Cassis et al. [54] used a proteinuric
mouse model of CKD and found that DAPA reduced the
number of glomerular lesions, proteinuria and podocyte
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Canagliflozin (CREDENCE)
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FIGURE 2: The primary cardiovascular and renal outcomes of the SGLT2 inhibitor outcome trials per baseline HbA1c subgroup. The primary
cardiovascular outcome was defined as 3-point MACEs. Renal outcomes were defined as a sustained 40% decrease of eGFR, renal replacement
therapy or renal death for the EMPA-REG OUTCOME trial; composite of doubling of serum creatinine, end-stage kidney disease or renal
death for the CANVAS trial; and a composite of doubling of serum creatinine, end-stage kidney disease and renal or cardiovascular death for
the CREDENCE trial. A description of the methods can be found in the Supplementary data.
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damage [54]. Another group examined the effects of the SGLT2
inhibitor luseogliflozin (LUSEO) in an acute renal injury model
and found that LUSEO attenuated endothelial rarefaction, in-
terstitial fibrosis and renal hypoxia. These effects were observed
together with an increase in vascular endothelial growth factor
(VEGF), suggesting the influence of a VEGF-dependent path-
way [55]. Finally, Jaikumkao et al. [56] examined the effects
of SGLT2 inhibition in a prediabetic obese rat model and
found that DAPA reduces hyperfiltration, microalbuminuria,
inflammation and tubulointerstitial fibrosis [56]. All together
the preclinical studies show contrary results. This is possibly
due to differences in designs and methods, such as differences
in group sizes, interspecies differences (mice versus rats), differ-
ences in types of experimental kidney diseases, differences in re-
searcher-induced levels of kidney damage or potential differences
in baseline eGFR and HbA1c levels.
To our knowledge, only two studies have examined the effects
of SGLT2 inhibitors in humans with non-diabetic CKD or risk
factors for CKD (Table 3). The first is a pilot study of Rajasekeran
et al. [57] examining the effects of DAPA on renal haemodynamics
and proteinuria in patients with FSGS [57]. Ten subjects with an
eGFR45 mL/min/1.73 m2 and urinary protein excretion between
30 mg and 6 g/day were treated with DAPA 10 mg/day for 8 weeks
on top of RAAS blocking therapy. DAPA increased 24-h urinary
glucose excretion and plasma haematocrit but, remarkably, had no
effect on BW, measured GFR, effective renal plasma flow (ERPF)
and proteinuria [57]. A post hoc sensitivity analysis did show
an effect on proteinuria, but only in subjects with a protein-
uria level below the median [57]. The second study is a trial
from Bays et al. [58] examining the effects of CANA in 376
non-diabetic obese subjects. They found a significant loss of
BW, a small decrease in eGFR and an increase in haemoglo-
bin, haematocrit and urinary glucose:creatinine ratio [58].
Other mechanistic, small-scale clinical trials in non-diabetic
CKD patients are still ongoing. Two of these trials are planned
to be published in 2020, DIAMOND (ClinicalTrials.gov,
Table 2. SGLT2 inhibitors in non-diabetic animals with kidney disease or risk factors for renal function decline
References Design Main outcomes Conclusion
Zhang et al. [52] 53 Sprague Dawley rats were assigned to
sham surgeryþ vehicle,
sham surgeryþDAPA or
subtotal nephrectomy (SNx)þ vehicle
SNxþDAPA
Treatment period: 12 weeks
DAPA versus vehicle: no change in SBP, 24-h
proteinuria excretion, and GFR; no effect on
glomerulosclerosis, tubulointerstitial fibrosis
and TGF-b1 mRNA overexpression
No renoprotective effects in a
non-diabetic rat model,
representing glomerular
hyperfiltration
Ma et al. [53] 20 C57BL/6N mice were assigned to
high oxalate dietþ vehicle or
high oxalate dietþEMPA
Treatment period: 7 or 14 days
EMPA versus vehicle: no effect on calcium
oxalate crystal deposition; no effect on GFR
decline, plasma creatinine and BUN; no
effect on tubular injury, inflammation and
fibrosis markers
No renoprotective effects in a
non-diabetic mouse model
with progressive CKD due
to tubulointerstitial disease
Zhang et al. [55] C57BL/6J mice were assigned to
Model 1: nephrectomy of the right
kidney and 11 days later
sham surgery or IR injury leftþ vehicle
or luseogliflozin (LUSEO);
Model 2: contralateral kidney was used
as a control and
sham surgery or IR injury leftþ vehicle
or LUSEO
Treatment period: 7 days
LUSEO versus vehicle: no effect on creatinine
clearance Week 1 post-IR. Preserved creati-
nine clearance at Week 4 attenuated TGF-b
expression, peritubular capillary congestion
and haemorrhage, tissue hypoxia and CD31-
positive cell loss at Week 1 and reduced re-
nal interstitial fibrosis at Week 4 increased
VEGF-A mRNA expression in Week 1.
Inhibition of VEGF by sunitinib inhibited
LUSEO-induced renoprotective effects
LUSEO attenuated endothelial
rarefaction, renal hypoxia
and renal interstitial
fibrosis after IR injury in
non-diabetic mice, possibly
via a VEGF-dependent
pathway
Cassis et al. [54] Unilateral nephrectomy was performed
and C57BL/6N mice were assigned to
control group (n¼ 12),
bovine serum albumin (BSA)
injectionsþ vehicle (n¼ 9),
BSAþDAPA (n¼ 8) or
BSAþ lisinopril (n¼ 8)
Treatment period: 23 days
DAPA and lisinopril reduced SBP. No effects
on BW and mGFR decline. DAPA and lisi-
nopril reduced UACR by 63 and 72%, re-
spectively. DAPA attenuated glomerular
lesions, macrophage infiltration and podo-
cyte loss. DAPA limited cytoskeletal remod-
elling in vitro
DAPA reduced proteinuria,
glomerular lesions and
limited podocyte loss in
non-diabetic proteinuric
mice
Jaikumkao
et al. [56]
Obese Wistar rats were assigned to
control group (n¼ 6),
high-fat diet (HFD) (n¼ 6),
HFD þ metformin (n¼ 6) or
HFD þ DAPA (n¼ 6)
Treatment period: 4 weeks
DAPA reduced renal hyperfiltration, microal
buminuria and expression of antioxidant en-
zyme superoxide dismutase, increased anti-
oxidant glutathione, suppressed markers of
inflammation and fibrosis and suppressed
the expression of endoplasmic reticulum
stress and renal pro-apoptotic proteins
DAPA decreased renal hyper-
filtration, microalbuminuria
and markers for renal
inflammation, tubulointer-
stitial fibrosis and apoptosis
in a prediabetic rat model
IR, ischaemia-reperfusion; SBP, systolic blood pressure; TGF, transforming growth factor; BUN, blood urea nitrogen; CD31, an endothelial marker.
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NCT03190694) and DAPASALT (NCT03152084). In 2020 and
2022, respectively, the results of large-scale long-term outcome
trials DAPA-CKD (NCT03036150) and EMPA-KIDNEY
(NCT03594110) are expected. These outcome trials and mecha-
nistic trials will add new information to the existing data of the
CREDENCE trial because these trials include patients without
diabetes mellitus, patients with an eGFR <30 mL/min/1.73 m2
and patients with non-proteinuric CKD.
C O N C L U S I O N
The data from recent trials show a pattern that suggests SGLT2
inhibitors are cardiovascular and renoprotective in patients
with lower renal functions, in patients with lower HbA1c levels
and in patients with non-diabetic kidney disease. However, the
available data are limited, especially in the non-diabetic CKD
population. Moreover, the current literature in the non-diabetic
population sometimes shows inconsistent results. Based on
these data, we can only hypothesize, but not yet conclude, that
SGLT2 inhibitors have renoprotective effects in non-diabetic
patients with CKD. Ongoing and future trials will have to prove
whether SGLT2 inhibitors are indeed effective in non-diabetic
patients with kidney diseases.
S U P P L E M E N T A R Y D A T A
Supplementary data are available at ndt online
C O N F L I C T O F I N T E R E S T S T A T E M E N T
C.C.J.D. and R.T.G. participate in an investigator-initiated
clinical trial with DAPA (DIAMOND, NCT03190694) for
which AstraZeneca provided the research medication.
Boehringer Ingelheim calculated and provided the numbers
of the EMPA-REG OUTCOME trial that were used to make
Figures 1 and 2.
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